Last reviewed · How we verify
ErythroPOietin Alfa to Prevent Mortality and Reduce Severe Disability in Critically Ill TRAUMA Patients (EPO-TRAUMA)
The EPO-TRAUMA study is a prospective, multi-centre, double-blind, phase III, randomised controlled trial evaluating the efficacy of epoetin alfa compared to placebo in reducing mortality and severe disability at six months in critically ill trauma patients. 2500 mechanically ventilated ICU patients admitted with a primary trauma diagnosis presenting to the ICU will be recruited into the study from participating study centres in Australia, New Zealand, Europe, and Saudi Arabia.
Details
| Lead sponsor | Australian and New Zealand Intensive Care Research Centre |
|---|---|
| Phase | PHASE3 |
| Status | RECRUITING |
| Enrolment | 2500 |
| Start date | Mon Nov 09 2020 00:00:00 GMT+0000 (Coordinated Universal Time) |
| Completion | Tue Aug 31 2027 00:00:00 GMT+0000 (Coordinated Universal Time) |
Conditions
- Trauma
- Traumatic Injury
- Traumatic Brain Injury
- Wounds and Injuries
- Penetrating Injury
- Blunt Injury
- Major Trauma
- Multiple Trauma
Interventions
- Epoetin Alfa 40000 UNT/ML
- Sodium Chloride 0.9%
Countries
New Zealand, Finland, Belgium, Saudi Arabia, Ireland, Germany, Slovenia, Australia, Switzerland